Breaking News, Collaborations & Alliances

BioNTech, MediLink Therapeutics Ink Global ADC Alliance

BioNTech to pay $70 million upfront and additional development, regulatory and commercial milestones, with a potential value of more than $1 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech entered into a strategic research collaboration and worldwide licensing agreement with MediLink Therapeutics based in China, to develop next-generation antibody-drug conjugates for cancer. BioNTech will pay $70 million upfront and additional development, regulatory and commercial milestones, with a potential value of more than $1 billion.   MediLink will grant the exclusive global right to develop, manufacture and commercialize its antibody-drug conjugate (ADC) assets targeting the HE...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters